Invitae Corporation
NVTA
Rangering i aksjer
#35791
Invitae Corporation operates as a medical genetics enterprise, striving to... Invitae Corporation operates as a medical genetics enterprise, striving to integrate genetic insights into mainstream medical practice to enhance healthcare outcomes for individuals in the United States, Canada, and internationally. The company provides a comprehensive suite of offerings, including genetic testing for various clinical specializations such as hereditary cancer, cardiovascular health, neurological disorders, pediatric conditions, oncology, metabolic ailments, and rare diseases, alongside digital health tools and health data services. Its clientele spans individual patients, healthcare providers, biopharmaceutical firms, and other collaborators. Established in 2010 as Locus Development, Inc., the company officially became Invitae Corporation in 2012 and is headquartered in San Francisco, California.
Aksjekurs
$0.016
Sist synkronisert: 2024-03-11
Markedsverdi
$3.27M
Endring (1 dag)
-5.33%
Endring (1 år)
5,233.33%
Land
US
Handel Invitae Corporation (NVTA)
Kategori
Healthcare
EPS for Invitae Corporation (NVTA)
EPS per September 2023 TTM: $-5.38
Ifølge de siste økonomiske rapportene og aksjekursen til Invitae Corporation er selskapets nåværende EPS (TTM) $-5.38. Ved slutten av 2022 hadde selskapet en EPS på $-13.18, en økning sammenlignet med EPS-en i 2021 som var $-1.80.
EPS-historikk for Invitae Corporation fra 2016 til 2026
EPS ved slutten av hvert år
| År | EPS | Endre |
|---|---|---|
| 2026 (TTM) | $-5.38 | -100.00% |
| 2023 | 0.00 | -100.00% |
| 2022 | $-13.18 | 632.22% |
| 2021 | $-1.80 | -59.73% |
| 2020 | $-4.47 | 68.05% |
| 2019 | $-2.66 | 37.11% |
| 2018 | $-1.94 | -26.79% |
| 2017 | $-2.65 | -12.25% |
| 2016 | $-3.02 | 0.00% |
EPS for lignende selskaper eller konkurrenter
| Selskap | EPS | EPS-forskjell | Land |
|---|---|---|---|
| $18.62 | -446.10% |
US
|
|
| $5.65 | -205.02% |
US
|
|
| $-1.36 | -74.72% |
US
|
|
| - | - |
CN
|
|
| $5.09 | -194.61% |
US
|
